undamentalytics Newsletter
Sign in

Neuphoria Therapeutics Inc. (NEUP) stock

Add to watchlist

Add holding +

NASDAQ: NEUP Nasdaq Biotechnology

Neuphoria Therapeutics Inc. is a US-listed company in the biotechnology industry. Its financial year ends in June.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: every model's value for Neuphoria Therapeutics Inc. is far from the share price, which usually points to a data problem (a merger, a share-count change, a one-off) rather than a bargain or a bubble.

Price vs value

Under review: limited reported history: available models are shown without a Buy/Hold/Sell rating. We'll show the comparison once resolved.

Neuphoria Therapeutics Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Funds12 adding, 5 cuttingOf 3 active managers that changed their stake, 3 added; quarter to June 30, 2026Fund buyers and sellers

The Fundamentalytics view

Current signal Free cash flow diverging from earnings: TTM free cash flow fell 2122.5% while net income fell 3539.3%: a 1417pp divergence.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

Nothing in Neuphoria Therapeutics Inc.'s latest figures clears our strength thresholds.

Things to watch

  • Share dilution. Diluted shares rose 170.9% in a year.
  • Volatile shares. Over the past year the shares showed annualised volatility of 55% and a beta of 0.9 against the S&P 500.

Latest results: FY2025 Q4

Filed September 18, 2026
Earnings per share
$0.26 against an average estimate of -$0.56: beat by 145.9%

Neuphoria Therapeutics' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-0.3%
  • 1 week-10.1%
  • 1 month-12.4%
  • This year-21.6%
  • 1 year-33.2%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

EPS (TTM, diluted)
$-3.06

Growth

Share count change
+170.9%

Cash

Free cash flow (TTM)
-$13M

Earnings

Last results
May 20, 2025

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Agreement
  2. Agreement

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Neuphoria Therapeutics Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: limited reported history: available models are shown without a Buy/Hold/Sell rating.

The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.

Valuation models

We value Neuphoria Therapeutics Inc. as an operating company, with every model that fits that kind of business. Cost of equity 11%: the 10-year Treasury yield (4.9%) plus a beta of 1.35 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: This model is withheld pending its input or assumption review.
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: This model is withheld pending its input or assumption review.
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: This model is withheld pending its input or assumption review.
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: This model is withheld pending its input or assumption review.
Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. ~$0.3 ~$0.6–$2.0 Left out: out of range vs price (0.09x)
Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. — Combined value withheld. Review the individual models and their assumptions.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Neuphoria Therapeutics Inc. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 20252026
Share price$7.10$4.37
Market value$12m$19m
+ Net debt (− = net cash)−$14m−$20m
Enterprise value−$3m−$655990
Multiples
Price / sales 0.7x16.4x
Price / earnings ——
Price / free cash flow ——
EV / EBITDA ——

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$2.43 −31% — −100%
Next −$2.46 −1% — 0%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is 0.0% on 90 days ago. In the last 30 days, 0 analysts raised Neuphoria Therapeutics Inc.'s forecast and 1 cut it.

Consensus EPS forecast Neuphoria Therapeutics Inc., last 90 days
−$3.00 −$2.00 −$1.00 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$2.43 Current fiscal year, 60 days ago: −$2.43 Current fiscal year, 30 days ago: −$2.43 Current fiscal year, 7 days ago: −$2.43 Current fiscal year, Now: −$2.43 −$2.43 Next fiscal year, 90 days ago: −$2.46 Next fiscal year, 60 days ago: −$2.46 Next fiscal year, 30 days ago: −$2.46 Next fiscal year, 7 days ago: −$2.46 Next fiscal year, Now: −$2.46 −$2.46

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$2.43−$2.46
60 days ago −$2.43−$2.46
30 days ago −$2.43−$2.46
7 days ago −$2.43−$2.46
Now −$2.43−$2.46

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.56 $0.26 +145.9%
Mar 2026 −$0.56 −$0.09 +83.9%
Dec 2025 −$0.56 $0.41 +173.2%
Sept 2025 −$1.31 −$4.41 −236.6%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

1 analysts, Oct 2026
Buy00%
Hold1100%
Sell00%

Monthly trend

  1. Oct 202611

Counts of recommendations published by analysts covering Neuphoria Therapeutics Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
0.1%
of tradable shares
Days to cover
0.43
at average volume
Short interest, 1 month
−74%
to October 15, 2026
Held by institutions
43%
of shares
Held by insiders
5.0%
of shares
Employees
1
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 20222023202420252026 to date
Return
NEUP−63%−68%−81%+13%−22%
Industry peers (median)−56%−17%−28%−5%−27%
S&P 500−18%+26%+25%+18%+11%
Months that ended higher
NEUP17%25%17%58%36%
S&P 50042%67%75%75%46%
Largest fall from a high during the year
NEUP−64%−80%−87%−81%−45%
S&P 500−25%−10%−8%−19%−9%

Worst fall since December 16, 2021: 99% from December 16, 2021 to November 4, 2024. Getting back needed a 7612% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$3.04 – $5.48
From 52-week high
−44.5%
vs 50-day average
−14.5%
vs 200-day average
−26.9%
Volatility (1 year)
55%
Beta vs S&P 500
0.90

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
1 up, 0 down
typical move ±12.5%
After a week
1 up, 0 down
typical move ±32.7%
After a month
1 up, 0 down
typical move ±38.4%
Results releasedNext dayS&P 500 next day5 days21 days
May 20, 2025 +12.5% −2.0% +32.7% +38.4%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Fundamentals

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q, 20-F, 20-F/A. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2025 Jun 2025 2026 Jun 2026
Income
Revenue 16 1
EBITDA −0 −16
Operating income −1 −16
Net income −0 −13
Diluted EPS −$0.23 −$3.06
Growth (year on year)
Revenue — −92.5%
Margins
EBITDA margin −3.0% <−999%
Operating margin −7.2% <−999%
Net margin −2.4% <−999%
Cash flow
Cash from operations 0 −12
Stock-based pay 0 0
Balance sheet
Cash 14 20
Total debt 0 0
Net debt (negative = net cash) −14 −20
Diluted shares 2m 4m

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 2 checks passed · June 30, 2026
What it owns · $29m
Short-term assets $21mLonger-term assets $8m
What it owes, and who funded it · $29m
Short-term liabilities $1mLonger-term liabilities $3mShareholders' equity $25m
  • Short-term assets cover short-term liabilities $21m of assets due within a year against $756,581 of liabilities due within a year.
  • Short-term assets cover long-term liabilities $21m short-term assets against $3m of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Neuphoria Therapeutics Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+170.9%
year over year

Who owns it

Funds buying and selling
Reported value
$8.7M
Institutions reporting
22
Shares held vs prior quarter
▲ 13.4%
Positions opened / closed
6 / 3

Top buyers and sellers, Q2 2026: 12 institutions bought and 5 sold ; the biggest buyer was Advisorshares Investments LLC (+98K shares) and the biggest seller Squadron Capital Management LLC (−77K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Lynx1 Capital Management LP $3.8M 875K 43.9% 0.0%
Advisorshares Investments LLC $1.1M 253K 12.7% ▲ 62.8%
Vanguard Capital Management LLC $758,143 173K 8.7% ▲ 76.1%
Shay Capital LLC $680,942 156K 7.8% ▲ 3.2%
Balyasny Asset Management L.P. $621,536 142K 7.1% 0.0%
Citadel Advisors LLC $317,083 73K 3.6% ▲ 275.4%
Geode Capital Management, LLC $216,384 50K 2.5% ▼ 4.8%
Ikarian Capital, LLC $207,326 47K 2.4% 0.0%
Vanguard Fiduciary Trust Co $147,732 34K 1.7% ▲ 0.6%
ADAR1 Capital Management, LLC $131,100 30K 1.5% 0.0%
Fny Investment Advisers, LLC $115,000 27K 1.3% 0.0%
Renaissance Technologies LLC $111,435 26K 1.3% New

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Neuphoria Therapeutics Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $0 net buying

No open-market insider trades reported in the last 12 months.

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

  • May 20, 2025

Recent SEC filings

Data status

When each part of this page on Neuphoria Therapeutics Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Neuphoria Therapeutics Inc. in brief

What does Neuphoria Therapeutics Inc. do?
Neuphoria Therapeutics Inc. is a US-listed company in the biotechnology industry. Its financial year ends in June.
What is Neuphoria Therapeutics Inc.'s stock ticker?
Neuphoria Therapeutics Inc. trades under the ticker NEUP on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
Who are Neuphoria Therapeutics Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Lynx1 Capital Management LP, Advisorshares Investments LLC and Vanguard Capital Management LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Neuphoria Therapeutics Inc.'s market cap?
On June 30, 2026, Neuphoria Therapeutics Inc.'s market capitalisation was about $19.2M and net debt of -$19.9M. Market figures come from third-party market data and may be delayed.